• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cognyte Elects Two New Board Members to Strengthen Expertise and Drive Growth

    2/18/25 8:00:00 AM ET
    $ALLT
    $BLRX
    $CGEN
    $CGNT
    Computer Communications Equipment
    Telecommunications
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALLT alert in real time by email

    Announcement reflects company's commitment to augment Board of Directors with industry-experienced executives from both the government and software sectors

    Cognyte Software Ltd. (NASDAQ:CGNT) ("Cognyte"), a global leader in investigative analytics software, today announced the appointment of two new members to its Board of Directors. Matthew O'Neill and Nurit Benjamini will join the board on March 1, 2025, and March 31, 2025, respectively, reflecting the company's commitment to add independent directors from the government and software sectors. Richard Nottenburg will be stepping down from his board position effective March 31, 2025.

    Having served with the United States Secret Service for over two decades, Mr. O'Neill brings significant law enforcement, government, financial crimes and security experience, along with established relationships within these communities. Ms. Benjamini has more than 20 years of experience as CFO in leading software companies, overseeing financial reporting for a diverse group of U.S.-listed technology firms. Together, these two directors are well-aligned with Cognyte's strategic goals of growing its business and expanding its North American presence.

    "We are pleased to welcome Matthew O'Neill and Nurit Benjamini as our two newest board members," said Earl Shanks, Chairman of Cognyte's Board of Directors. "These latest appointments reflect our commitment to further strengthen the board with deep industry and business experience. Matthew brings significant domain expertise in security and a strong understanding of U.S. federal agency practices and procedures. Nurit has extensive experience working in the software sector, where she has led finance, operations, legal and strategic initiatives across different roles and domains. We are excited to have both Matthew and Nurit with us as we continue to drive consistent long-term growth at Cognyte."

    "We sincerely appreciate Richard's valuable contributions and guidance during his tenure on the Cognyte board," added Mr. Shanks. "Richard played a key role in establishing Cognyte as an independent company with market leading technology and a solid foundation for sustainable growth."

    Mr. O'Neill served until December 2023 as the Deputy Special Agent in Charge of Cyber Operations at the United States Secret Service, where he directed the agency's global cyber investigative strategies and oversaw efforts to dismantle transnational criminal networks. During his tenure, he served as the Director of the Asset Forfeiture Branch and as the Director of the Global Investigative Operations Center, where he established the Secret Service's first agencywide criminal investigative fusion center. Mr. O'Neill holds certifications from Carnegie Mellon University and American University and earned his Bachelor of Science degree from James Madison University. He currently serves as Co-Founder and Partner at 5OH Consulting LLC.

    Ms. Benjamini is a Partner and CFO at F2 Venture Capital, bringing over 20 years of experience as a CFO for leading software companies, including CrazyLabs Ltd., Wix (NASDAQ:WIX), CopperGate Communications Ltd. and Compugen (NASDAQ:CGEN). Throughout her career, Ms. Benjamini has played a pivotal role in leading technology companies through fundraising, M&A and IPO processes. Currently, she serves as an external director at Caesarstone Ltd. (NASDAQ:CSTE), having previously served as a board member of BioLineRx (NASDAQ:BLRX) and Allot Ltd. (NASDAQ:ALLT). Ms. Benjamini holds a Bachelor of Arts degree in economics and business and a Master of Business Administration degree in finance, both from Bar Ilan University, Israel.

    About Cognyte Software Ltd.

    Cognyte Software Ltd. is a global leader in investigative analytics software that empowers a variety of government and other organizations with Actionable Intelligence for a Safer World™. Our open interface software is designed to help customers accelerate and improve the effectiveness of investigations and decision-making. Hundreds of customers rely on our solutions to accelerate and conduct investigations and derive insights, with which they identify, neutralize, and tackle threats to national security and address different forms of criminal and terror activities. Learn more at www.cognyte.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250218582211/en/

    Investor Relations Contact:

    Dean Ridlon

    Cognyte Software

    [email protected]

    Get the next $ALLT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALLT
    $BLRX
    $CGEN
    $CGNT

    CompanyDatePrice TargetRatingAnalyst
    Wix.com Ltd.
    $WIX
    4/3/2026$96.00Buy → Neutral
    UBS
    Wix.com Ltd.
    $WIX
    4/2/2026$96.00Buy → Neutral
    UBS
    Wix.com Ltd.
    $WIX
    3/27/2026$91.00Neutral → Underweight
    Analyst
    Wix.com Ltd.
    $WIX
    3/12/2026$98.00Neutral
    Piper Sandler
    Wix.com Ltd.
    $WIX
    3/9/2026$90.00Outperform → Neutral
    Robert W. Baird
    Allot Ltd.
    $ALLT
    1/12/2026$15.00Overweight
    Cantor Fitzgerald
    Compugen Ltd.
    $CGEN
    1/7/2026$4.00Buy
    H.C. Wainwright
    Wix.com Ltd.
    $WIX
    11/20/2025$200.00 → $140.00Buy
    Needham
    More analyst ratings

    $ALLT
    $BLRX
    $CGEN
    $CGNT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for APHEXDA issued to BIOLINERX, LTD.

    Submission status for BIOLINERX, LTD.'s drug APHEXDA (ORIG-1) with active ingredient MOTIXAFORTIDE has changed to 'Approval' on 09/08/2023. Application Category: NDA, Application Number: 217159, Application Classification: Type 1 - New Molecular Entity

    9/11/23 2:15:50 PM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLT
    $BLRX
    $CGEN
    $CGNT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Wix Announces Final Results of Modified Dutch Auction Tender Offer

    NEW YORK—Wix.com Ltd. (NASDAQ:WIX) ("Wix" or the "Company") today announced the final results of its "modified Dutch Auction" tender offer, which expired at one (1) minute after 11:59 P.M., New York City time, on April 1, 2026.  Based on the final count by Equiniti Trust Company, LLC, the depositary for the tender offer (the "Depositary"), a total of 17,577,250 of Wix's ordinary shares, par value NIS 0.01 per share (each, a "Share," and collectively, the "Shares"), were properly tendered and not properly withdrawn at or below the purchase price of $92.00 per Share. Not all Shares tendered through notice of guaranteed delivery were delivered within the required settlement period.  Wix has a

    4/3/26 7:00:00 AM ET
    $WIX
    Computer Software: Programming Data Processing
    Technology

    Wix Announces Preliminary Results of Modified Dutch Auction Tender Offer

    NEW YORK, April 2, 2026—Wix.com Ltd. (NASDAQ:WIX) ("Wix" or the "Company") today announced the preliminary results of its "modified Dutch Auction" tender offer, which expired at one (1) minute after 11:59 P.M., New York City time, on April 1, 2026.  Based on the preliminary count by Equiniti Trust Company, LLC, the depositary for the tender offer (the "Depositary"), a total of 18,718,009 of Wix's ordinary shares, par value NIS 0.01 per share (each, a "Share," and collectively, the "Shares"), were properly tendered and not properly withdrawn at or below the purchase price of $92.00 per share. In accordance with the terms and conditions of the tender offer, and based on the preliminary count

    4/2/26 7:00:00 AM ET
    $WIX
    Computer Software: Programming Data Processing
    Technology

    Allot Files Annual Report on Form 20-F for the Year Ended December 31, 2025

    Hod Hasharon, Israel, March 27, 2026 (GLOBE NEWSWIRE) -- Allot (NASDAQ:ALLT) (TASE: ALLT), a leading global provider of innovative Security-as-a-Service (SECaaS) and Deep Network Intelligence solutions for communication service providers and enterprises, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission ("SEC"). The annual report on Form 20-F, which contains its audited financial statements, can be accessed on the SEC's website at http://www.sec.gov as well as on the Company's investor relations website at https://investors.allot.com/financial-information/sec-filings. The Company wi

    3/27/26 11:25:39 AM ET
    $ALLT
    Computer Communications Equipment
    Telecommunications

    $ALLT
    $BLRX
    $CGEN
    $CGNT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Topline Capital Partners, Lp bought $6,114,211 worth of shares (969,631 units at $6.31), increasing direct ownership by 12% to 9,020,184 units (SEC Form 4)

    4 - Cognyte Software Ltd. (0001824814) (Issuer)

    9/12/24 6:40:00 PM ET
    $CGNT
    Computer Software: Prepackaged Software
    Technology

    See Explanation in Footnotes Topline Capital Management, Llc bought $6,114,211 worth of shares (969,631 units at $6.31) (SEC Form 4)

    4 - Cognyte Software Ltd. (0001824814) (Issuer)

    9/12/24 6:31:23 PM ET
    $CGNT
    Computer Software: Prepackaged Software
    Technology

    $ALLT
    $BLRX
    $CGEN
    $CGNT
    SEC Filings

    View All

    Amendment: SEC Form SC TO-I/A filed by Wix.com Ltd.

    SC TO-I/A - Wix.com Ltd. (0001576789) (Subject)

    4/3/26 7:19:59 AM ET
    $WIX
    Computer Software: Programming Data Processing
    Technology

    SEC Form SCHEDULE 13G filed by Wix.com Ltd.

    SCHEDULE 13G - Wix.com Ltd. (0001576789) (Subject)

    4/2/26 4:45:46 PM ET
    $WIX
    Computer Software: Programming Data Processing
    Technology

    Amendment: SEC Form SC TO-I/A filed by Wix.com Ltd.

    SC TO-I/A - Wix.com Ltd. (0001576789) (Subject)

    4/2/26 7:12:14 AM ET
    $WIX
    Computer Software: Programming Data Processing
    Technology

    $ALLT
    $BLRX
    $CGEN
    $CGNT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wix.com downgraded by UBS with a new price target

    UBS downgraded Wix.com from Buy to Neutral and set a new price target of $96.00

    4/3/26 10:44:59 AM ET
    $WIX
    Computer Software: Programming Data Processing
    Technology

    Wix.com downgraded by UBS with a new price target

    UBS downgraded Wix.com from Buy to Neutral and set a new price target of $96.00

    4/2/26 8:06:34 AM ET
    $WIX
    Computer Software: Programming Data Processing
    Technology

    Wix.com downgraded by Analyst with a new price target

    Analyst downgraded Wix.com from Neutral to Underweight and set a new price target of $91.00

    3/27/26 8:45:14 AM ET
    $WIX
    Computer Software: Programming Data Processing
    Technology

    $ALLT
    $BLRX
    $CGEN
    $CGNT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Levine Zurit

    4 - COMPUGEN LTD (0001119774) (Issuer)

    4/3/26 7:31:38 AM ET
    $CGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Ophir Eran

    4 - COMPUGEN LTD (0001119774) (Issuer)

    4/3/26 7:29:40 AM ET
    $CGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Panem Sandra

    3 - BioLineRx Ltd. (0001498403) (Issuer)

    3/31/26 4:03:52 PM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLT
    $BLRX
    $CGEN
    $CGNT
    Leadership Updates

    Live Leadership Updates

    View All

    Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors

    HOLON, Israel, Feb. 12, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced the appointment of Michele Holcomb, Ph.D., as a new independent director, effective February 11, 2026. "On behalf of Compugen's Board of Directors, I am delighted to welcome Michele to the Board," said Anat Cohen-Dayag, Ph.D., Executive Chair, Compugen. "Michele brings more than three decades of experience spanning the biotech, pharmaceuticals and healthcare services industries. Her unique blend of strategic insights, corporate development, innovation and firsthand operation

    2/12/26 7:00:00 AM ET
    $CGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    PayPal and Wix Advance Strategic Relationship to Deliver Unified Payments Experience for Merchants

    PayPal integrates with Wix Payments, providing a consolidated view for merchants to streamline payment management, enhance conversions and meet growing demand for flexible payment options  NEW YORK – Wix.com Ltd. (NASDAQ:WIX), the leading SaaS website builder platform globally1, today announced an expansion of its partnership with PayPal Holdings Inc. (NASDAQ:PYPL), bringing additional online payment options to merchants through Wix Payments. Now available as a built-in part of Wix Payments, this provides U.S.-based merchants a unified, seamless experience that simplifies backend operations and ultimately supports higher checkout conversion.  With this deeper integration, PayPal is now ava

    7/24/25 9:00:00 AM ET
    $PYPL
    $WIX
    Diversified Commercial Services
    Industrials
    Computer Software: Programming Data Processing
    Technology

    Cognyte Appoints Distinguished Innovator Ronny Lempel as Chief Technology Officer to Guide AI-Focused Research

    25+ years of technology expertise and leadership will continue to cultivate innovation for sustained company growth Cognyte Software Ltd. (NASDAQ:CGNT) ("Cognyte"), a global leader in investigative analytics software, today announced the appointment of Dr. Ronny Lempel as Chief Technology Officer (CTO). In this role, Lempel will apply over 25 years of proven, cross-discipline technology expertise to extend Cognyte's innovation leadership and bring unparalleled vision and value to Cognyte's customers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250318301357/en/Cognyte appointed Dr. Ronny Lempel as Chief Technology Officer (CTO

    3/18/25 8:00:00 AM ET
    $CGNT
    Computer Software: Prepackaged Software
    Technology

    $ALLT
    $BLRX
    $CGEN
    $CGNT
    Financials

    Live finance-specific insights

    View All

    Cognyte Reports Fourth Quarter and Fiscal Year 2026 Financial Results

    Reports strong Q4 and full-year results with double-digit growth, and operating leverage driving faster profitability growth Guides to fiscal 2027 revenue of approximately $448 million with additional margin expansion Cognyte Software Ltd. (NASDAQ:CGNT) (the "Company," "Cognyte," "we," "us" and "our"), a global leader in software-driven technology for investigative analytics, today announced results for the three months and year ended January 31, 2026 ("Q4 FYE26" and "FYE26"). Financial Summary for Three Months Ended January 31, 2026 Q4 FYE26 Revenue was $106.2 million, up approximately 12.4% compared to the same period last year. Q4 FYE26 GAAP operating income was $5.2 million,

    3/25/26 7:05:00 AM ET
    $CGNT
    Computer Software: Prepackaged Software
    Technology

    BioLineRx Reports 2025 Financial Results and Provides Corporate Update

    - On track to initiate Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM) by end of this month -- GLIX1 is positioned to potentially address unmet needs for novel and more effective cancer treatments by targeting DNA damage response mechanisms -- Management to host conference call today, March 23, at 8:30 am EDT -TEL AVIV, Israel, March 23, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its audited financial results for the year ended December 31, 2025, and provided a corporate update. "Since our last quarterly update, we have been

    3/23/26 7:00:00 AM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioLineRx to Report 2025 Annual Results on March 23, 2026

    Management to Hold Conference Call at 8:30 a.m. EDTTEL AVIV, Israel, March 16, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its audited financial results for the year ended December 31, 2025 on Monday, March 23, 2026, before the U.S. markets open. The Company will host a conference call at 8:30 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer.To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be acce

    3/16/26 7:00:00 AM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLT
    $BLRX
    $CGEN
    $CGNT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Allot Ltd.

    SC 13G - Allot Ltd. (0001365767) (Subject)

    11/18/24 9:00:22 AM ET
    $ALLT
    Computer Communications Equipment
    Telecommunications

    Amendment: SEC Form SC 13G/A filed by Caesarstone Ltd.

    SC 13G/A - Caesarstone Ltd. (0001504379) (Subject)

    11/14/24 6:21:59 AM ET
    $CSTE
    Building Materials
    Industrials

    Amendment: SEC Form SC 13G/A filed by Cognyte Software Ltd.

    SC 13G/A - Cognyte Software Ltd. (0001824814) (Subject)

    11/12/24 4:07:25 PM ET
    $CGNT
    Computer Software: Prepackaged Software
    Technology